Pathway to Cures’ investment in Spark Biomedical is an example of how we foster the development of innovative approaches to healthcare access and unmet medical needs in the blood and bleeding disorders community.Spark Biomedical’s hemostasis…
This session explores the latest advances and challenges in research focused on children and adolescents with inherited bleeding disorders, such as hemophilia, von Willebrand disease, and other rare conditions. Our expert speakers will…
Roche (and Roche group member Chugai) recently presented data from a phase I/II clinical study of their investigational bispecific antibody therapy NXT007, in people with hemophilia A who do not have factor VIII inhibitors. NXT007 is being…
Historically, women and girls affected by hemophilia have experienced protracted delays in securing an accurate diagnosis and care that takes bleeding disorders into full account. A newly published paper takes a 200+ year view of this history and…
Hemab Therapeutics recently presented clinical and preclinical stage data associated with two of their investigational therapies - Sutacimig (formerly HMB-001) and HMB-002. Hemab is a biotechnology company that specializes in the development of…
This week, Congress passed a bill, the “One Big Beautiful Bill Act,” that will have widespread impacts on the bleeding disorders community – together with millions of others across the country who get health insurance through Medicaid or the…
Dr. Kyle Davis is a board-certified Pediatric Hematologist-Oncologist at the Indiana Hemophilia and Thrombosis Center (IHTC).
Federal: Action Alert on H.R. 1 (Budget Reconciliation): As of July 1, 200 bleeding disorders advocates had taken more than 300 actions to contact Members of Congress in response to NBDF’s Grassroots Action…